Olympus Backed This Endoscopy Robot, Then Took an Option on Its Rival

Olympus invested in Neptune Medical in August 2024. Eleven months later it co-founded a company to build a competing robot, and took an option to buy that one outright. On September 18 Neptune's system cleared the FDA. The company Olympus can own outright is still early stage.

A 510(k) for a colonoscopy robot

The Triton 1 is a robotic endoscopy system, and the FDA cleared it through the 510(k) pathway for diagnostic and therapeutic work in the colon: screening, surveillance, endoscopic mucosal resection, endoscopic submucosal dissection. The pitch is stability. A colonoscope that wanders gives an incomplete look at the wall, and an incomplete look is how adenomas get missed.

Neptune's evidence is the CARE 1 study, released in May: fifty patients, a 54.2 percent adenoma detection rate, no adverse events. The 35 percent it beats is the industry benchmark for adenoma detection. A fifty-patient study measured against a benchmark is enough to clear a 510(k), and enough to open a conversation with a gastroenterology chief. It isn't enough to carry a value analysis committee against an incumbent whose scopes are already in the room.

Olympus bought into this market twice, on different terms

Neptune raised $97 million in a Series D in August 2024. Sonder Capital and Olympus Corporation of the Americas were both in that round, and the company named Fred Moll chairman of the board in the same announcement.

On July 25, 2025, Olympus and Revival Healthcare Capital co-founded Swan EndoSurgical to build an endoluminal robotic system for the GI tract. The initial combined investment was at least $65 million, and the structure runs up to $458 million if the milestones land. Olympus holds an option to acquire Swan at a predetermined value.

In Neptune, Olympus owns a piece of a company it doesn't control, building a product that competes with its own scopes. In Swan, Olympus owns a path to the whole thing at a price it already agreed to.

What the strategic investor gets

A strategic investor gets what a financial investor doesn't: a working read on your technology, your timelines, and how hard the problem turns out to be. Olympus held that read for eleven months before it co-founded Swan. I have no way to know whether the two decisions were connected, and it changes little either way. The read was already theirs.

You pay for that read in control. You never negotiated its terms, you can't switch it off yourself, and nothing in the term sheet says when Olympus starts building its own. That decision sits in their roadmap, and you don't get to read that one.

The question before a strategic round closes isn't whether the partner is trustworthy. Most of them are, inside their own incentives. The question is what this investor learns about my company that they can't buy anywhere else, and what they could build with it. If the answer is that they learn how hard the problem is and how long it takes, you've funded someone else's build-versus-buy analysis with your own operating data.

Neptune's counter is the calendar. Triton is cleared and Swan is still early stage, and a clearance is the one asset an option can't replicate. Every month Neptune spends putting systems in front of gastroenterologists is a month of procedure data and surgeon muscle memory that Olympus would have to buy back later.

Dave Saunders is the founder of Base Reality Group and a Fractional CPO for product companies. He was a founder and operator at Galen Robotics, where the surgical-robotics platform earned FDA De Novo authorization in 2023, and he managed a 35-patent portfolio licensed from Johns Hopkins. He wrote Founders Who Finish and publishes The Build. More about Dave →